You just read:

PDS Biotechnology Signs Agreement with National Cancer Institute to form Phase II clinical collaboration for novel cancer immunotherapies based on PDS' Versamune® platform technology

News provided by

PDS Biotechnology Corporation

Feb 09, 2016, 06:00 ET